PROTHENA CORPORATION PUBLIC LIMITED COMPANY Revenue
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Revenue of $1.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $1.01M, a 77.15% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $51.08M, a 1706.36% increase year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $21.00K, a 99.01% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $2.42M, a 148.97% increase year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY revenue from contract with customer, excluding assessed tax for fiscal 2025 was $9.68M, a 92.83% decline from fiscal 2024.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY revenue from contract with customer, excluding assessed tax for fiscal 2024 was $135.16M, a 47.92% increase from fiscal 2023.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY revenue from contract with customer, excluding assessed tax for fiscal 2023 was $91.37M, a 69.50% increase from fiscal 2022.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY revenue from contract with customer, excluding assessed tax for fiscal 2022 was $53.91M, a 73.13% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.01M 10-Q · filed 2026-08-06 | $52.09M 10-Q · filed 2026-08-06 | $52.12M derived: sum of 3 quarters · filed 2026-08-06 | $54.53M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $51.08M 10-Q · filed 2026-05-07 | $51.10M derived: sum of 2 quarters · filed 2026-05-07 | $53.52M derived: sum of 3 quarters · filed 2026-05-07 | $57.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $2.44M derived: sum of 2 quarters · filed 2026-02-27 | $6.86M derived: sum of 3 quarters · filed 2026-08-06 | $9.68M 10-K · filed 2026-02-27 |
| 2025-09-30 | $2.42M 10-Q · filed 2025-11-06 | $6.83M derived: sum of 2 quarters · filed 2026-08-06 | $9.66M 10-Q · filed 2025-11-06 | $11.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $4.42M 10-Q · filed 2026-08-06 | $7.25M 10-Q · filed 2026-08-06 | $9.37M derived: sum of 3 quarters · filed 2026-08-06 | $10.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.83M 10-Q · filed 2026-05-07 | $4.95M derived: sum of 2 quarters · filed 2026-05-07 | $5.92M derived: sum of 3 quarters · filed 2026-05-07 | $137.94M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $3.09M derived: sum of 2 quarters · filed 2026-02-27 | $135.11M derived: sum of 3 quarters · filed 2026-02-27 | $135.16M 10-K · filed 2026-02-27 |
| 2024-09-30 | $970.00K 10-Q · filed 2025-11-06 | $132.98M derived: sum of 2 quarters · filed 2025-11-06 | $133.03M 10-Q · filed 2025-11-06 | $133.35M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $132.01M 10-Q · filed 2025-08-04 | $132.06M 10-Q · filed 2025-08-04 | $132.38M derived: sum of 3 quarters · filed 2026-02-27 | $217.25M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $50.00K 10-Q · filed 2025-05-08 | $366.00K derived: sum of 2 quarters · filed 2026-02-27 | $85.23M derived: sum of 3 quarters · filed 2026-02-27 | $89.25M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $316.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $85.18M derived: sum of 2 quarters · filed 2026-02-27 | $89.20M derived: sum of 3 quarters · filed 2026-02-27 | $91.37M 10-K · filed 2026-02-27 |
| 2023-09-30 | $84.87M 10-Q · filed 2024-11-12 | $88.89M derived: sum of 2 quarters · filed 2024-11-12 | $91.05M 10-Q · filed 2024-11-12 | $140.98M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $4.02M 10-Q · filed 2024-08-08 | $6.19M 10-Q · filed 2024-08-08 | $56.11M derived: sum of 3 quarters · filed 2025-02-27 | $57.63M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $2.17M 10-Q · filed 2024-05-08 | $52.09M derived: sum of 2 quarters · filed 2025-02-27 | $53.61M derived: sum of 3 quarters · filed 2025-02-27 | $54.92M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $49.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $51.44M derived: sum of 2 quarters · filed 2025-02-27 | $52.75M derived: sum of 3 quarters · filed 2025-02-27 | $53.91M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.52M 10-Q · filed 2023-11-02 | $2.83M derived: sum of 2 quarters · filed 2023-11-02 | $3.98M 10-Q · filed 2023-11-02 | $5.15M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $1.31M 10-Q · filed 2023-08-03 | $2.46M 10-Q · filed 2023-08-03 | $3.64M derived: sum of 3 quarters · filed 2024-02-22 | $142.81M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $1.15M 10-Q · filed 2023-05-04 | $2.33M derived: sum of 2 quarters · filed 2024-02-22 | $141.50M derived: sum of 3 quarters · filed 2024-02-22 | $201.57M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $140.35M derived: sum of 2 quarters · filed 2024-02-22 | $200.42M derived: sum of 3 quarters · filed 2024-02-22 | $200.58M 10-K · filed 2024-02-22 |
| 2021-09-30 | $139.17M 10-Q · filed 2022-11-03 | $199.25M derived: sum of 2 quarters · filed 2022-11-03 | $199.41M 10-Q · filed 2022-11-03 | $199.76M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $60.07M 10-Q · filed 2022-08-08 | $60.23M 10-Q · filed 2022-08-08 | $60.59M derived: sum of 3 quarters · filed 2022-08-08 | $60.75M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $160.00K 10-Q · filed 2022-05-05 | $520.00K derived: sum of 2 quarters · filed 2022-05-05 | $677.00K derived: sum of 3 quarters · filed 2022-05-05 | $872.00K derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $360.00K 10-K · filed 2021-02-26 | $517.00K derived: sum of 2 quarters · filed 2021-11-04 | $712.00K derived: sum of 3 quarters · filed 2021-11-04 | $853.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | $157.00K 10-Q · filed 2021-11-04 | $352.00K derived: sum of 2 quarters · filed 2021-11-04 | $493.00K 10-Q · filed 2021-11-04 | $749.00K derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $195.00K 10-Q · filed 2021-08-05 | $336.00K 10-Q · filed 2021-08-05 | $592.00K derived: sum of 3 quarters · filed 2021-08-05 | $797.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $141.00K 10-Q · filed 2021-05-11 | $397.00K derived: sum of 2 quarters · filed 2021-05-11 | $602.00K derived: sum of 3 quarters · filed 2021-05-11 | $769.00K derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $256.00K 10-K · filed 2021-02-26 | $461.00K derived: sum of 2 quarters · filed 2021-02-26 | $628.00K derived: sum of 3 quarters · filed 2021-02-26 | $814.00K 10-K · filed 2022-02-25 |
| 2019-09-30 | $205.00K 10-K · filed 2021-02-26 | $372.00K derived: sum of 2 quarters · filed 2021-02-26 | $558.00K 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $167.00K 10-K · filed 2021-02-26 | $353.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $186.00K 10-K · filed 2021-02-26 | |||
| 2018-12-31 | $955.00K 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |